Cancer is a battle many people fight everyday. Both patients and families are effected by the physical, emotional and financial strains of the chronic condition. For years, the traditional form of cancer treatment has been through Chemotherapy. Chemotherapy, commonly known as chemo, is a cancer treatment that uses a combination of anti-cancer drugs to destroy cancer cells. While it is the most common form of cancer treatment, it is not the only option. Chemotherapy has a high probability of introducing harmful toxins to the body, and producing side effects rendering patients incapable of performing routine activities on their own. Being educated and informed on the side effects of chemotherapy, and the other options available could greatly improve the quality of life for cancer patients.
Co-founder of Biotechnology company Seattle Genetics Clay Siegall is committed to delivering alternative cancer treatment options to patients and their families. As an industry leader in antibody-drug conjugates, they have earned their mark at the top of innovative cancer treatment options. Unlike chemotherapy, ADCs target and kill cancer cells through the use of monoclonal antibodies, and harness the potential to enhance anti-tumor activity. Choosing an ADC treatment may also reduce the risk of toxic effects associated with traditional chemotherapy. ADCETRIS is the first ADC released by Seattle Genetics, with the help of Takeda Pharmaceutical Company. The new ADC is currently available in over 50 countries.
In an effort to reach more patients, Seattle Genetics is conducting a large scale clinical development program that will serve to assess the potency of the ACDs in regards to lymphoma and non-lymphoma patients. Through the development program, and their partnership with Takeda Pharmaceutical Company, Seattle Genetics received complete commercialization rights to ADCETRIS in the United States and Canada. When Seattle Genetics was founded, they had one goal. Cancer patients needed more options, and more education on their condition. With the introduction of ADCETRIS, slowly but surly, they are changing the world of cancer treatment, attacking one cell at a time.